Is Biomea Fusion, Inc. (BMEA) a Buy, Sell, or Hold?
NASDAQ : BMEA
Biomea Fusion, Inc.
$1.3 USD
$0.04 (3.17%)
- Volume
- 367.3K
- Average Volume
- 1.24M
- Market Capitalization
- $77.35M
- P/E Ratio
- -1.47
- Dividend Yield
- 0.00%
- Price Target
- $19.00
- Year High
- $2.99
- Year Low
- $0.87
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $4.98
Company Overview
NASDAQ
Michael J. Hitchcock
Biotechnology
Healthcare
BMEA
40
US
USD
Liquidity Metrics
0.07
4.98
4.98
4.81
0.00
Sales & Valuation
-$
0.00
5.02
-1.38
-0.78
Profitability
-$1.18
-$61.8M
0.00%
0.00%
-196.72%
-96.91%
P/E Metrics
-1.47
-0.01
-0.01
Analyst Price Target & Rating
$19.00
$40.00
$10.00
2/5
13 Analysts
-93.16%
Poll Results
About Biomea Fusion, Inc. (NASDAQ:BMEA) Stock
Biomea Fusion, Inc. is a biopharmaceutical firm dedicated to discovering and developing innovative covalent small molecule therapies. These treatments are specifically designed for individuals suffering from genetically defined cancers and various metabolic ailments. The company's primary drug candidate, BMF-219, is a potent and selective covalent inhibitor of menin, engineered for oral administration. Menin plays a crucial role as a transcriptional regulator in the abnormal signaling pathways found across numerous cancer types. Established in 2017, Biomea Fusion's operations are headquartered in Redwood City, California. ...
2026-06-05 19:32:00
•Translational data presented at ADA demonstrate icovamenib's potential to promote muscle preservation and fat reduction, supporting its broader therapeutic utility in obesity and diabetes, including as a complementary therapy alongside GLP-1 receptor agonists to enhance metabolic health outcomes • Clinical data presented at ADA from COVALENT-112 show improvements in HbA1c and C-peptide in type 1 diabetes patients treated with icovamenib, with no evidence of immune activation, and inflammatory markers stable or reduced • Additionally, the Company expanded its Phase I BMF-650 study to evaluate a rapid one-step titration and enhanced weight loss potential with its oral GLP-1 receptor agonist SAN CARLOS, Calif.
2026-06-05 19:32:00
•Translational data presented at ADA demonstrate icovamenib's potential to promote muscle preservation and fat reduction, supporting its broader therapeutic utility in obesity and diabetes, including as a complementary therapy alongside GLP-1 receptor agonists to enhance metabolic health outcomes • Clinical data presented at ADA from COVALENT-112 show improvements in HbA1c and C-peptide in type 1 diabetes patients treated with icovamenib, with no evidence of immune activation, and inflammatory markers stable or reduced • Additionally, the Company expanded its Phase I BMF-650 study to evaluate a rapid one-step titration and enhanced weight loss potential with its oral GLP-1 receptor agonist
2026-06-03 08:00:00
Collaboration will Assess the Potential Impact of the Combination of Icovamenib and Semaglutide on Physical Function, Body Weight, Body Composition, Muscle Health and Metabolic Outcomes Late-Breaking Preclinical Findings at the American Diabetes Association Annual Meeting June 5-8 Highlighting Potential Mechanisms through which Icovamenib may Support Metabolic Health SAN CARLOS, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced a collaboration with the University of Leicester as part of the ongoing platform research study titled Investigating and Optimizing Physical Function with Weight Loss: A Multi-Arm Open Label Adaptive Platform Trial (OPAL) which is being led by Professors Melanie Davies and Thomas Yates at the University of Leicester and Leicester Diabetes Centre (LDC).
Biomea Fusion to Participate at Upcoming Investor Conferences
2026-05-12 16:05:00
SAN CARLOS, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that management will participate in the following investor conferences: H.C.
Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights
2026-05-11 16:54:00
SAN CARLOS, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today reported its financial results for the first quarter ended March 31, 2026, and provided a business update.
2026-05-07 09:11:14
Biomea Fusion, Inc. (BMEA) Discusses Developments in Diabetes With Emphasis on Icovamenib and Clinical Trial Insights Transcript
2026-05-05 17:50:00
SAN CARLOS, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that three icovamenib abstracts have been selected for late-breaking poster presentations at the American Diabetes Association (ADA) 86th Scientific Sessions, taking place June 5–8, 2026 in New Orleans. The presentations include data from icovamenib, the Company's investigational oral menin inhibitor, across both type 1 and type 2 diabetes, highlighting its potential to improve beta cell function and support metabolic health.
2026-04-28 17:41:33
Biomea Fusion, Inc. (BMEA) Discusses Top Line Results From COVALENT-112 Trial of Icovamenib in Type 1 Diabetes Transcript
Frequently Asked Questions
-
What is the current Biomea Fusion, Inc. (BMEA) stock price?
-
Biomea Fusion, Inc.(NASDAQ:BMEA) stock price is $1.3 in the last trading session. During the trading session, BMEA stock reached the peak price of $2.99 while $0.872 was the lowest point it dropped to. The percentage change in BMEA stock occurred in the recent session was 3.17% while the dollar amount for the price change in BMEA stock was $0.04.
-
BMEA's industry and sector of operation?
-
The NASDAQ listed BMEA is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of BMEA?
-
Caroline Perez- Dupont | Senior Vice President of Legal
Heow Tan | Chief Technology & Quality Officer
Michael J. Hitchcock | Interim Chief Executive Officer & Director
Stephan Morris | Chief Development Officer
Ravi Upasani | Executive Vice President of Intellectual Property -
How many employees does BMEA have?
-
Number of BMEA employees currently stands at 40. BMEA operates from 1599 Industrial Road, San Carlos, CA 94063, US.
-
Link for BMEA official website?
-
Official Website of BMEA is: https://biomeafusion.com
-
How do I contact BMEA?
-
BMEA could be contacted at phone #650 980 9099 and can also be accessed through its website. BMEA operates from 1599 Industrial Road, San Carlos, CA 94063, US.
-
How many shares of BMEA are traded daily?
-
The average number of BMEA shares traded daily for last 3 months was 1.24M.
-
What is the market cap of BMEA currently?
-
The market value of BMEA currently stands at $77.35M with its latest stock price at $1.3